 Biogen Idec Inc. reported positive interim results from an early-stage study of an Alzheimer’s disease drug, sending the company’s shares higher and renewing debate about drugs that attack amyloid plaques in the brain.. The study, which is still under way, is testing Biogen’s drug against a placebo in 200 patients with early forms of Alzheimer’s. Interim results showed the drug reduced beta amyloid levels in the brain, and had a “statistically significant effect on cognition” after 54 weeks of treatment, Biogen’s research and...
  